A citation-based method for searching scientific literature

Koichi Takahashi, Boyu Hu, Feng Wang, Yuanqing Yan, Ekaterina Kim, Candida Vitale, Keyur P Patel, Paolo Strati, Curtis Gumbs, Latasha Little, Samantha Tippen, Xingzhi Song, Jianhua Zhang, Nitin Jain, Philip Thompson, Guillermo Garcia-Manero, Hagop Kantarjian, Zeev Estrov, Kim-Anh Do, Michael Keating, Jan A Burger, William G Wierda, P Andrew Futreal, Alessandra Ferrajoli. Blood 2018
Times Cited: 29







List of co-cited articles
245 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mutations driving CLL and their evolution in progression and relapse.
Dan A Landau, Eugen Tausch, Amaro N Taylor-Weiner, Chip Stewart, Johannes G Reiter, Jasmin Bahlo, Sandra Kluth, Ivana Bozic, Mike Lawrence, Sebastian Böttcher,[...]. Nature 2015
647
44

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Carmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, Janine Altmüller, Holger Thiele, Jasmin Bahlo, Sandra Kluth, Giuliano Crispatzu, Marco Herling, Joanna Schiller,[...]. Blood 2016
91
34

Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner, S Stilgenbauer, A Benner, E Leupolt, A Kröber, L Bullinger, K Döhner, M Bentz, P Lichter. N Engl J Med 2000
34

Non-coding recurrent mutations in chronic lymphocytic leukaemia.
Xose S Puente, Silvia Beà, Rafael Valdés-Mas, Neus Villamor, Jesús Gutiérrez-Abril, José I Martín-Subero, Marta Munar, Carlota Rubio-Pérez, Pedro Jares, Marta Aymerich,[...]. Nature 2015
565
31

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Ferran Nadeu, Julio Delgado, Cristina Royo, Tycho Baumann, Tatjana Stankovic, Magda Pinyol, Pedro Jares, Alba Navarro, David Martín-García, Sílvia Beà,[...]. Blood 2016
208
27

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
Xose S Puente, Magda Pinyol, Víctor Quesada, Laura Conde, Gonzalo R Ordóñez, Neus Villamor, Georgia Escaramis, Pedro Jares, Sílvia Beà, Marcos González-Díaz,[...]. Nature 2011
27

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
Lili Wang, Michael S Lawrence, Youzhong Wan, Petar Stojanov, Carrie Sougnez, Kristen Stevenson, Lillian Werner, Andrey Sivachenko, David S DeLuca, Li Zhang,[...]. N Engl J Med 2011
809
24

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Michael Hallek, Bruce D Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi,[...]. Blood 2018
671
24

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
T J Hamblin, Z Davis, A Gardiner, D G Oscier, F K Stevenson. Blood 1999
24

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba,[...]. Blood 2014
364
20

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
J R Brown, P Hillmen, S O'Brien, J C Barrientos, N M Reddy, S E Coutre, C S Tam, S P Mulligan, U Jaeger, P M Barr,[...]. Leukemia 2018
168
20


Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Philip A Thompson, Susan M O'Brien, William G Wierda, Alessandra Ferrajoli, Francesco Stingo, Susan C Smith, Jan A Burger, Zeev Estrov, Nitin Jain, Hagop M Kantarjian,[...]. Cancer 2015
178
20

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Davide Rossi, Silvia Rasi, Valeria Spina, Alessio Bruscaggin, Sara Monti, Carmela Ciardullo, Clara Deambrogi, Hossein Khiabanian, Roberto Serra, Francesco Bertoni,[...]. Blood 2013
336
17

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R Furman, Jeff P Sharman, Steven E Coutre, Bruce D Cheson, John M Pagel, Peter Hillmen, Jacqueline C Barrientos, Andrew D Zelenetz, Thomas J Kipps, Ian Flinn,[...]. N Engl J Med 2014
17

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Susan O'Brien, Richard R Furman, Steven Coutre, Ian W Flinn, Jan A Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao,[...]. Blood 2018
281
17

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
R N Damle, T Wasil, F Fais, F Ghiotto, A Valetto, S L Allen, A Buchbinder, D Budman, K Dittmar, J Kolitz,[...]. Blood 1999
17

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Dan A Landau, Scott L Carter, Petar Stojanov, Aaron McKenna, Kristen Stevenson, Michael S Lawrence, Carrie Sougnez, Chip Stewart, Andrey Sivachenko, Lili Wang,[...]. Cell 2013
989
17


Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
F Nadeu, G Clot, J Delgado, D Martín-García, T Baumann, I Salaverria, S Beà, M Pinyol, P Jares, A Navarro,[...]. Leukemia 2018
71
17

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Michael Hallek, Bruce D Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J Keating, Emili Montserrat, Kanti R Rai,[...]. Blood 2008
17

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Alexander C Leeksma, Justin Taylor, Bian Wu, Jeffrey R Gardner, Jie He, Michelle Nahas, Mithat Gonen, Wendimagegn G Alemayehu, Doreen Te Raa, Tatjana Walther,[...]. Leukemia 2019
37
17

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
569
17

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Roland Schmitz, Ryan M Young, Michele Ceribelli, Sameer Jhavar, Wenming Xiao, Meili Zhang, George Wright, Arthur L Shaffer, Daniel J Hodson, Eric Buras,[...]. Nature 2012
576
17

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.
Lu Jiang, Zhao-Hui Gu, Zi-Xun Yan, Xia Zhao, Yin-Yin Xie, Zi-Guan Zhang, Chun-Ming Pan, Yuan Hu, Chang-Ping Cai, Ying Dong,[...]. Nat Genet 2015
221
17

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Xavier C Badoux, Michael J Keating, Xuemei Wang, Susan M O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian,[...]. Blood 2011
147
13

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Barbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, Raymonde Busch, Gabor Kovacs, Christian Maurer, Elisabeth Lange, Hubert Köppler, Michael Kiehl, Martin Sökler,[...]. Lancet Oncol 2016
396
13

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, John Gerecitano, Tadeusz Robak, Javier De la Serna,[...]. N Engl J Med 2018
483
13

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Andrew W Roberts, Matthew S Davids, John M Pagel, Brad S Kahl, Soham D Puvvada, John F Gerecitano, Thomas J Kipps, Mary Ann Anderson, Jennifer R Brown, Lori Gressick,[...]. N Engl J Med 2016
13

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke, Christian Maurer,[...]. Blood 2016
445
13

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
A R Mato, B T Hill, N Lamanna, P M Barr, C S Ujjani, D M Brander, C Howlett, A P Skarbnik, B D Cheson, C S Zent,[...]. Ann Oncol 2017
145
13

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Mary Ann Anderson, Constantine Tam, Thomas E Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David C S Huang,[...]. Blood 2017
119
13

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.
Giulia Fabbri, Silvia Rasi, Davide Rossi, Vladimir Trifonov, Hossein Khiabanian, Jing Ma, Adina Grunn, Marco Fangazio, Daniela Capello, Sara Monti,[...]. J Exp Med 2011
454
13

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.
Kristian Cibulskis, Michael S Lawrence, Scott L Carter, Andrey Sivachenko, David Jaffe, Carrie Sougnez, Stacey Gabriel, Matthew Meyerson, Eric S Lander, Gad Getz. Nat Biotechnol 2013
13

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Neus Giménez, Alejandra Martínez-Trillos, Arnau Montraveta, Mónica Lopez-Guerra, Laia Rosich, Ferran Nadeu, Juan G Valero, Marta Aymerich, Laura Magnano, Maria Rozman,[...]. Haematologica 2019
31
13

Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Tatjana Pandzic, Jimmy Larsson, Liqun He, Snehangshu Kundu, Kenneth Ban, Muhammad Akhtar-Ali, Anders R Hellström, Anna Schuh, Ruth Clifford, Stuart J Blakemore,[...]. Clin Cancer Res 2016
18
22

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Carmen D Herling, Nima Abedpour, Jonathan Weiss, Anna Schmitt, Ron Daniel Jachimowicz, Olaf Merkel, Maria Cartolano, Sebastian Oberbeck, Petra Mayer, Valeska Berg,[...]. Nat Commun 2018
121
13

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
Víctor Quesada, Laura Conde, Neus Villamor, Gonzalo R Ordóñez, Pedro Jares, Laia Bassaganyas, Andrew J Ramsay, Sílvia Beà, Magda Pinyol, Alejandra Martínez-Trillos,[...]. Nat Genet 2011
732
13

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
S Jeromin, S Weissmann, C Haferlach, F Dicker, K Bayer, V Grossmann, T Alpermann, A Roller, A Kohlmann, T Haferlach,[...]. Leukemia 2014
169
13

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Davide Rossi, Marco Fangazio, Silvia Rasi, Tiziana Vaisitti, Sara Monti, Stefania Cresta, Sabina Chiaretti, Ilaria Del Giudice, Giulia Fabbri, Alessio Bruscaggin,[...]. Blood 2012
217
13

Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.
Bruno M Grande, Daniela S Gerhard, Aixiang Jiang, Nicholas B Griner, Jeremy S Abramson, Thomas B Alexander, Hilary Allen, Leona W Ayers, Jeffrey M Bethony, Kishor Bhatia,[...]. Blood 2019
99
13

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
903
13

SF3B1 mutations in chronic lymphocytic leukemia.
Youzhong Wan, Catherine J Wu. Blood 2013
78
10

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Philip A Thompson, Constantine S Tam, Susan M O'Brien, William G Wierda, Francesco Stingo, William Plunkett, Susan C Smith, Hagop M Kantarjian, Emil J Freireich, Michael J Keating. Blood 2016
346
10

Chronic lymphocytic leukemia.
Nicholas Chiorazzi, Kanti R Rai, Manlio Ferrarini. N Engl J Med 2005
10

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Binsah George, Danelle James, Hagop Kantarjian, Jan Burger,[...]. Blood 2015
267
10

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.
J L Binet, A Auquier, G Dighiero, C Chastang, H Piguet, J Goasguen, G Vaugier, G Potron, P Colona, F Oberling,[...]. Cancer 1981
10

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C Byrd, Jennifer R Brown, Susan O'Brien, Jacqueline C Barrientos, Neil E Kay, Nishitha M Reddy, Steven Coutre, Constantine S Tam, Stephen P Mulligan, Ulrich Jaeger,[...]. N Engl J Med 2014
10

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jeffrey A Jones, Tadeusz Robak, Jennifer R Brown, Farrukh T Awan, Xavier Badoux, Steven Coutre, Javier Loscertales, Kerry Taylor, Elisabeth Vandenberghe, Malgorzata Wach,[...]. Lancet Haematol 2017
140
10

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Alessandra Ferrajoli, Bang-Ning Lee, Ellen J Schlette, Susan M O'Brien, Hui Gao, Sijin Wen, William G Wierda, Zeev Estrov, Stefan Faderl, Evan N Cohen,[...]. Blood 2008
322
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.